Eventide Asset Management - Q2 2022 holdings

$4.68 Billion is the total value of Eventide Asset Management's 136 reported holdings in Q2 2022. The portfolio turnover from Q1 2022 to Q2 2022 was 22.9% .

 Value Shares↓ Weighting
BHVN SellBIOHAVEN PHARMACTL HLDG CO L$164,521,000
-15.1%
1,129,100
-30.9%
3.52%
+15.8%
MTD SellMETTLER TOLEDO INTERNATIONAL$140,724,000
-19.0%
122,500
-3.2%
3.01%
+10.6%
ARGX SellARGENX SEsponsored adr$121,014,000
-7.0%
319,400
-22.6%
2.59%
+27.0%
FIVN SellFIVE9 INC$113,724,000
-18.2%
1,247,800
-0.9%
2.43%
+11.6%
ASND SellASCENDIS PHARMA A/Ssponsored adr$111,459,000
-28.6%
1,199,000
-9.8%
2.38%
-2.5%
CTAS SellCINTAS CORP$105,746,000
-14.2%
283,100
-2.2%
2.26%
+17.2%
NEP SellNEXTERA ENERGY PARTNERS LP$96,158,000
-30.7%
1,296,627
-22.1%
2.06%
-5.4%
TT SellTRANE TECHNOLOGIES PLC$94,026,000
-17.0%
724,000
-2.4%
2.01%
+13.3%
ROP SellROPER TECHNOLOGIES INC$93,414,000
-36.7%
236,700
-24.2%
2.00%
-13.5%
IDXX SellIDEXX LABS INC$90,243,000
-41.4%
257,300
-8.7%
1.93%
-20.1%
DLO SellDLOCAL LTD$89,655,000
-23.9%
3,415,443
-9.4%
1.92%
+3.8%
KRTX SellKARUNA THERAPEUTICS INC$78,360,000
-17.4%
619,400
-17.2%
1.68%
+12.8%
TTD SellTHE TRADE DESK INC$76,520,000
-45.8%
1,826,685
-10.4%
1.64%
-26.0%
LOW SellLOWES COS INC$76,436,000
-14.3%
437,600
-0.7%
1.64%
+17.0%
HUBS SellHUBSPOT INC$65,161,000
-37.3%
216,733
-0.9%
1.39%
-14.4%
ENTG SellENTEGRIS INC$59,574,000
-45.1%
646,630
-21.8%
1.27%
-25.1%
SPT SellSPROUT SOCIAL INC$57,544,000
-31.6%
990,943
-5.6%
1.23%
-6.6%
GNRC SellGENERAC HLDGS INC$56,793,000
-48.7%
269,700
-27.5%
1.22%
-29.9%
EXAS SellEXACT SCIENCES CORP$53,791,000
-48.4%
1,365,600
-8.3%
1.15%
-29.5%
DHI SellD R HORTON INC$51,727,000
-34.6%
781,500
-26.4%
1.11%
-10.7%
LRCX SellLAM RESEARCH CORP$48,368,000
-50.1%
113,500
-37.1%
1.03%
-31.9%
GLBE SellGLOBAL E ONLINE LTD$47,467,000
-43.7%
2,353,371
-5.7%
1.02%
-23.2%
A SellAGILENT TECHNOLOGIES INC$42,543,000
-21.7%
358,200
-12.7%
0.91%
+6.9%
ASML SellASML HOLDING N V$32,836,000
-52.1%
69,000
-32.7%
0.70%
-34.6%
KURA SellKURA ONCOLOGY INC$32,813,000
-1.0%
1,790,144
-13.1%
0.70%
+35.3%
HASI SellHANNON ARMSTRONG SUST INFR C$31,146,000
-27.9%
822,664
-9.6%
0.67%
-1.6%
CWEN SellCLEARWAY ENERGY INCcl c$29,349,000
-47.5%
842,400
-44.9%
0.63%
-28.2%
REXR SellREXFORD INDL RLTY INC$28,869,000
-35.2%
501,293
-16.0%
0.62%
-11.6%
VRSK SellVERISK ANALYTICS INC$27,314,000
-22.9%
157,800
-4.4%
0.58%
+5.2%
NVT SellNVENT ELECTRIC PLC$26,919,000
-12.3%
859,200
-2.7%
0.58%
+19.8%
MDB SellMONGODB INCcl a$22,317,000
-43.7%
86,000
-3.8%
0.48%
-23.2%
BPMC SellBLUEPRINT MEDICINES CORP$22,149,000
-41.5%
438,500
-26.0%
0.47%
-20.1%
SellDICE THERAPEUTICS INC$20,778,000
-41.0%
1,370,261
-26.8%
0.44%
-19.6%
NDAQ SellNASDAQ INC$18,290,000
-17.2%
119,900
-3.3%
0.39%
+13.0%
SNPS SellSYNOPSYS INC$17,055,000
-30.0%
56,157
-23.1%
0.36%
-4.2%
ADCT SellADC THERAPEUTICS SA$14,946,000
-48.5%
1,879,959
-4.8%
0.32%
-29.7%
NRIX SellNURIX THERAPEUTICS INC$14,621,000
-44.2%
1,154,000
-38.3%
0.31%
-23.7%
BCYC SellBICYCLE THERAPEUTICS PLCsponsored ads$14,327,000
-74.2%
853,800
-32.4%
0.31%
-64.8%
KLAC SellKLA CORP$14,048,000
-43.1%
44,028
-34.7%
0.30%
-22.5%
ELS SellEQUITY LIFESTYLE PPTYS INC$11,388,000
-34.8%
161,600
-29.2%
0.24%
-10.6%
EPIX SellESSA PHARMA INC$10,602,000
-58.9%
3,365,568
-19.3%
0.23%
-43.8%
WD SellWALKER & DUNLOP INC$9,108,000
-42.3%
94,535
-22.5%
0.20%
-21.1%
PRAX SellPRAXIS PRECISION MEDICINES I$8,619,000
-80.8%
3,518,062
-20.0%
0.18%
-73.8%
VITL SellVITAL FARMS INC$8,313,000
-69.3%
950,092
-56.6%
0.18%
-58.0%
MRTX SellMIRATI THERAPEUTICS INC$7,586,000
-79.7%
113,000
-75.1%
0.16%
-72.3%
TRGP SellTARGA RES CORP$6,326,000
-42.9%
106,022
-27.7%
0.14%
-22.0%
PLD SellPROLOGIS INC.$5,825,000
-78.4%
49,513
-70.4%
0.12%
-70.4%
GRMN SellGARMIN LTD$5,473,000
-24.4%
55,700
-8.7%
0.12%
+3.5%
SNV SellSYNOVUS FINL CORP$5,123,000
-70.1%
142,100
-59.3%
0.11%
-59.0%
DSGN SellDESIGN THERAPEUTICS INC$3,942,000
-39.0%
281,569
-29.6%
0.08%
-16.8%
WMS SellADVANCED DRAIN SYS INC DEL$3,607,000
-47.7%
40,052
-31.0%
0.08%
-28.7%
MNDY SellMONDAY COM LTD$2,105,000
-59.0%
20,409
-37.2%
0.04%
-43.8%
CIEN SellCIENA CORP$1,462,000
-43.9%
32,000
-25.6%
0.03%
-24.4%
KBH SellKB HOME$999,000
-78.2%
35,100
-75.2%
0.02%
-70.8%
ETTX ExitENTASIS THERAPEUTICS HLDGS I$0-590,602
-100.0%
-0.02%
BOLT ExitBOLT BIOTHERAPEUTICS INC$0-859,826
-100.0%
-0.04%
BRKS ExitAZENTA INC$0-29,700
-100.0%
-0.04%
OM ExitOUTSET MED INC$0-69,000
-100.0%
-0.05%
CRDF ExitCARDIFF ONCOLOGY INC$0-1,467,922
-100.0%
-0.06%
FOUR ExitSHIFT4 PMTS INCcl a$0-70,000
-100.0%
-0.07%
ExitENPHASE ENERGY INCnote 3/0$0-4,463,000
-100.0%
-0.07%
IMGN ExitIMMUNOGEN INC$0-1,000,000
-100.0%
-0.08%
APTVPRA ExitAPTIV PLC5.5% cnv pfd a$0-94,500
-100.0%
-0.20%
XNCR ExitXENCOR INC$0-500,755
-100.0%
-0.21%
CGEM ExitCULLINAN ONCOLOGY INC$0-1,440,145
-100.0%
-0.24%
ExitPALO ALTO NETWORKS INCnote 0.750% 7/0$0-6,810,000
-100.0%
-0.25%
ExitNCINO INC$0-416,200
-100.0%
-0.27%
SNDX ExitSYNDAX PHARMACEUTICALS INC$0-1,165,000
-100.0%
-0.32%
SMAR ExitSMARTSHEET INC$0-697,000
-100.0%
-0.60%
DT ExitDYNATRACE INC$0-2,386,741
-100.0%
-1.76%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2022-08-15
Signatures

The EDGAR filing(s) were signed by:

About Eventide Asset Management

Eventide Asset Management is a Boston-based investment firm that specializes in providing investment solutions to investors who are looking for long-term growth opportunities. The company was founded in 2008 by a group of experienced investment professionals who shared a common vision of creating a firm that would focus on investing in companies that are making a positive impact on society.

The company's investment philosophy is based on the belief that companies that are making a positive impact on society are more likely to be successful in the long run. Eventide's investment team conducts extensive research to identify companies that are aligned with this philosophy and have the potential to deliver strong returns over the long term.

The company's investment strategies are managed by a team of experienced professionals, including CEO Robin John, COO Finny Kuruvilla, and Chief Investment Officer, Dr. Finny Kuruvilla. The team has a proven track record of delivering strong returns to investors, and their investment strategies have been recognized by industry experts.

Eventide Asset Management offers a range of investment solutions, including mutual funds, separately managed accounts, and exchange-traded funds (ETFs). The company's funds are available to individual investors, financial advisors, and institutional investors.

Overall, Eventide Asset Management is a reputable investment firm that has a strong focus on investing in companies that are making a positive impact on society. The company's experienced investment team and proven track record make it a compelling option for investors who are looking for long-term growth opportunities.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
LOWES COS INC40Q3 20233.2%
PALO ALTO NETWORKS INC40Q3 20233.6%
ASML HOLDINGS NV40Q3 20231.9%
NEUROCRINE BIOSCIENCES INC40Q3 20231.1%
REPLIGEN CORP40Q3 20230.5%
VERACYTE INC38Q3 20231.5%
LAM RESEARCH CORP35Q3 20233.4%
XPO LOGISTICS INC34Q1 20233.8%
COLLEGIUM PHARMACEUTICAL INC34Q3 20232.6%
MAGNA INTL INC33Q4 20212.5%

View Eventide Asset Management's complete holdings history.

Latest significant ownerships (13-D/G)
Eventide Asset Management Q2 2022 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
Cogent Biosciences, Inc.February 14, 20232,589,7783.7%
ESSA Pharma Inc.Sold outFebruary 14, 202300.0%
Freeline Therapeutics Holdings plcFebruary 14, 20235,920,7659.1%
KnowBe4, Inc.Sold outFebruary 14, 202300.0%
Praxis Precision Medicines, Inc.February 14, 20233,518,0627.5%
Prometheus Biosciences, Inc.February 14, 20231,032,9382.2%
SUTRO BIOPHARMA, INC.Sold outFebruary 14, 202300.0%
Vital Farms, Inc.Sold outFebruary 14, 202300.0%
Zymeworks Inc.Sold outFebruary 14, 202300.0%
Entasis Therapeutics Holdings Inc.February 14, 2022590,6021.2%

View Eventide Asset Management's complete significant-ownership history.

Latest filings
TypeFiled
13F-HR/A2024-02-20
13F-HR2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14

View Eventide Asset Management's complete filings history.

Compare quarters

Export Eventide Asset Management's holdings